GSK reduces price for its first line treatment for chronic hepatitis B

National price negotiations deliver a positive outcome for patients in China: GSK reduces price for its first line treatment for chronic hepatitis B

GSK China today committed to reduce the price of its first-line chronic hepatitis B (CHB) treatment, patent-protected Viread® (tenofovir disoproxil fumarate)1, in China by up to 67%. This follows an announcement on the outcomes of a national price negotiation pilot by the National Health and Family Planning Commission (NHFPC) and other relevant government agencies.

Once fully implemented, the price of Viread in China for the treatment of CHB will be lower than all other countries and be covered by the country's reimbursement policies. This commitment will significantly expand access for CHB patients living in China to this internationally recommended first-line treatment.

Hervé Gisserot, Senior Vice President and General Manager, Pharmaceuticals and Vaccines, GSK China/Hong Kong, said, “Supporting the government's initiative is an important aspect of GSK's commitment to be in China, with China, for China. We are proud that Viread has been included in the Chinese government's efforts to add innovative medicines to the reimbursement policies. This represents a defining moment in the government's efforts to provide high quality, innovative products at more affordable prices, and ultimately improve patient outcomes in China”.

Viread was approved by the China Food and Drug Administration for use in China in October, 2013 for the treatment of CHB in adults and pediatric patients 12 years of age and older. International and national treatment guidelines recommend Viread as a first line treatment for CHB.  Eight-year clinical data demonstrates the treatment has a good tolerability profile and efficacy with zero drug related resistance as verified so far. 

According to the NHFPC, it is estimated that 7.18% of the Chinese population test positive for the hepatitis B surface antigen (HBsAg), with 28 million CHB patients needing timely and appropriate antiviral treatment. Several international societies recently issued a joint statement urging governments, healthcare organisations and NGOs to work together to eliminate the health burden of viral hepatitis. They urged organisations to implement and finance healthcare programmes to better diagnose and treat individuals with CHB and Hepatitis C virus according to the accepted practice guidelines.2

Professor Jia Ji-dong, former Chairman of the International Society of Hepatitis and Deputy Director of Chinese Foundation for Hepatitis Prevention and Control (CFHPC), said, “Multi-party collaboration led by the government is critical to breaking the bottleneck of CHB treatment and reducing the disease burden. I believe that increasing numbers of patients will benefit if tenofovir, the first line treatment option, is made more affordable and included in the national reimbursement system as soon as possible”.

The price reduction on Viread is the latest example of GSK delivering on its publically stated commitment to be “in China, with China, for China”. Previous announcements include:

  • Intent to reduce the price of our Hepatitis B treatment portfolio by 20 to 30%.
  • Transforming our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.
  • Partnering with Shanghai-based Desano Pharmaceuticals to announce the local manufacture of Tivicay® (dolutegravir), our new HIV medicine and one of our most commercially successful products, in July 2015.
  • Partnering with the National Health and Family Planning Commission on a multi-year programme to fund independent training programmes in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.
  • Launching a Beijing-based Institute for Public Health and Infectious Disease to conduct local development programmes for pivotal HIV and TB R&D assets in March 2016.


GSK – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit 

GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.

GSK enquiries:
Susan Song                 (Shanghai)


1 The compound patent for Viread is ZL97197460.8, normal expiry July 2017.

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2014.